Literature DB >> 31983581

Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability.

Catherine Daly1, Natalia A Molodecky2, Meghana Sreevatsava3, Asalif D Belayneh4, Shoukat A Chandio5, Jeff Partridge6, Ahmed Shaikh7, Mumtaz Laghari8, John Agbor9, Rana M Safdar10, Umar Farooq Bullo11, Safi M Malik10, Abdirahman Mahamud2.   

Abstract

The first large-scale vaccination campaign using needle-free jet injectors to administer fractional doses of inactivated poliovirus vaccine (fIPV) was conducted in Karachi, Pakistan, in February 2019. Data on acceptability of jet injectors were collected from 610 vaccinators and 4898 caregivers during the first four days of the campaign. Of those with prior needle and syringe experience, both vaccinators and caregivers expressed a strong preference for jet injectors (578/592 [97.6%] and 4792/4813 [99.6%], respectively), citing ease of use, appearance, and child's response to vaccination. Among caregivers, 4638 (94.7%) stated they would be more likely to bring their child for vaccination in a future campaign that used jet injectors. Mean vaccine coverage among towns administering fIPV was 98.7% - an increase by 18.4% over the preceding campaign involving full-dose IPV. Our findings demonstrate the strong acceptability of fIPV jet injectors and highlight the potential value of this method in future mass campaigns.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Fractional-dose IPV; Jet injector; Needle-free; Pakistan; Polio

Year:  2020        PMID: 31983581     DOI: 10.1016/j.vaccine.2019.12.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS.

Authors:  Martha Sedegah; Michael R Hollingdale; Harini Ganeshan; Maria Belmonte; Jun Huang; Arnel Belmonte; Sandra Inoue; Rachel Velasco; Bradley Hickey; Nimfa Teneza-Mora; Joanne Lumsden; Sharina Reyes; Jo Glenna Banania; Anatalio Reyes; Ivelese Guzman; Thomas L Richie; Judith E Epstein; Eileen Villasante
Journal:  PLoS One       Date:  2021-08-20       Impact factor: 3.240

2.  Needle-Free Jet Injectors and Nanosuspensions: Exploring the Potential of an Unexpected Pair.

Authors:  Michele Schlich; Luca Casula; Aurora Musa; Rosa Pireddu; Giulia Pitzanti; Maria Cristina Cardia; Donatella Valenti; Salvatore Marceddu; Anna Maria Fadda; Maria Antonietta De Luca; Chiara Sinico; Francesco Lai
Journal:  Pharmaceutics       Date:  2022-05-19       Impact factor: 6.525

3.  An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan.

Authors:  Umar Farooq Bullo; Jaishri Mehraj; Syed Musa Raza; Shumaila Rasool; Noreen Naz Ansari; Ahmed Ali Shaikh; Zamir Ali Phul; Sohail Ahmed Memon; Rehan Iqbal Baloch; Zahoor Ahmed Baloch; Shoukat Ali Chandio
Journal:  BMC Public Health       Date:  2021-01-06       Impact factor: 3.295

Review 4.  Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.

Authors:  Birgitte Giersing; Natasha Shah; Debra Kristensen; Jean-Pierre Amorij; Anna-Lea Kahn; Kristoffer Gandrup-Marino; Courtney Jarrahian; Darin Zehrung; Marion Menozzi-Arnaud
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 3.641

5.  A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.

Authors:  John J Suschak; Sandra L Bixler; Catherine V Badger; Kristin W Spik; Steven A Kwilas; Franco D Rossi; Nancy Twenhafel; Melissa L Adams; Charles J Shoemaker; Erin Spiegel; Jay W Hooper
Journal:  NPJ Vaccines       Date:  2022-04-22       Impact factor: 9.399

6.  Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia.

Authors:  Adedapo O Bashorun; Mariama Badjie Hydara; Ikechukwu Adigweme; Ama Umesi; Baba Danso; Njilan Johnson; Ngally Aboubacarr Sambou; Sidat Fofana; Francis J Kanu; Visalakshi Jeyaseelan; Harish Verma; William C Weldon; M Steven Oberste; Roland W Sutter; David Jeffries; Miriam Wathuo; Ondrej Mach; Ed Clarke
Journal:  Lancet Glob Health       Date:  2021-12-21       Impact factor: 26.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.